Vector Labs Ab04701-3.3 Anti-EGFRvIII [806], Mouse IgG2b, Fc Silent™, kappa (100 μg) Centrifuge Bundle Savings at Sycamore Life Sciences

Description

Product Class: Purified
Clone ID: 806
Heavy Chain Modification: Fc Silent™
Synonyms: de2-7 EGFR; delta2–7 epidermal growth factor receptor; ERBB1; ERBB; ErbB-1, Erb-B1; HER1; Epidermal growth factor receptor; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1
Amount: 100 μg
Application Codes Clone: therapeutic; FC; ELISA
Shipping Temperature: Wet Ice
Buffer Composition: PBS with 0.02% Proclin 300.
Original Format: IgG2b
Storage Temperature: Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Specificity Statement: This antibody is specific for the human delta2–7 epidermal growth factor receptor (de2–7 EGFR or EGFRvIII) which is a truncated version of the EGFR commonly expressed in glioma. This antibody also binds overexpressed wild-type (wt) EGFR but not native EGFR expressed in normal tissues at physiological levels. EGFR is a transmembrane mitogenic glycoprotein with a cytoplasmically facing tyrosine kinase site which is activated by binding of the epidermal growth factor in the external domain. It also binds transforming growth factor alpha (TGFa). EGFR a member of the epidermal growth factor family and is closely related to receptor tyrosine kinases. This receptor tyrosine kinase binds ligands of the EGF family and activates signaling cascades to convert extracellular cues into appropriate cellular responses. Mutations that lead to EGFR overexpression (known as upregulation) or overactivity have been associated with a number of cancers, including lung cancer, anal cancers and glioblastoma multiforme as well as inflammatory diseases.
Application Notes: This antibody bound de2-7 EGFR (EGFRvIII) transfected U87MG glioma cells with high affinity but did not bind parental cells that express the wild type EGFR in a flow cytometric assay. This antibody can bind wild type EGFR containing the extracellular domain only in certain conditions like when the extracellular domain was immobilized on the surface of ELISA plates (PMID: 11920591). The antitumor activity of this antibody against human tumor xenografts grown in nude mice was studied. This antibody significantly inhibited the growth of U87 MG xenografts transfected with the de2–7 EGFR in a dose-dependent manner. It further also inhibited growth of new and established A431 xenografts, a cell line expressing >10^6 EGFRs/cell (PMID: 11454674). The efficacy of this antibody, on the growth of intracranial xenografted gliomas in nude mice was also studied. It was reported that treatment of U87 MG.DEGFR tumors in mice with mAb 806 caused decreases in both tumor growth and angiogenesis, as well as increased apoptosis. In vivo mAb 806 treatment resulted in reduced phosphorylation of the constitutively active DEGFR and caused down-regulated expression of the apoptotic protector, Bcl-XL (PMID: 11454673).

Product Class:	Purified
Clone ID:	806
Heavy Chain Modification:	Fc Silent™
Synonyms:	de2-7 EGFR; delta2–7 epidermal growth factor receptor; ERBB1; ERBB; ErbB-1, Erb-B1; HER1; Epidermal growth factor receptor; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1
Amount:	100 μg
Application Codes Clone:	therapeutic; FC; ELISA
Shipping Temperature:	Wet Ice
Buffer Composition:	PBS with 0.02% Proclin 300.
Original Format:	IgG2b
Storage Temperature:	Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Specificity Statement:	This antibody is specific for the human delta2–7 epidermal growth factor receptor (de2–7 EGFR or EGFRvIII) which is a truncated version of the EGFR commonly expressed in glioma. This antibody also binds overexpressed wild-type (wt) EGFR but not native EGFR expressed in normal tissues at physiological levels. EGFR is a transmembrane mitogenic glycoprotein with a cytoplasmically facing tyrosine kinase site which is activated by binding of the epidermal growth factor in the external domain. It also binds transforming growth factor alpha (TGFa). EGFR a member of the epidermal growth factor family and is closely related to receptor tyrosine kinases. This receptor tyrosine kinase binds ligands of the EGF family and activates signaling cascades to convert extracellular cues into appropriate cellular responses. Mutations that lead to EGFR overexpression (known as upregulation) or overactivity have been associated with a number of cancers, including lung cancer, anal cancers and glioblastoma multiforme as well as inflammatory diseases.
Application Notes:	This antibody bound de2-7 EGFR (EGFRvIII) transfected U87MG glioma cells with high affinity but did not bind parental cells that express the wild type EGFR in a flow cytometric assay. This antibody can bind wild type EGFR containing the extracellular domain only in certain conditions like when the extracellular domain was immobilized on the surface of ELISA plates (PMID: 11920591). The antitumor activity of this antibody against human tumor xenografts grown in nude mice was studied. This antibody significantly inhibited the growth of U87 MG xenografts transfected with the de2–7 EGFR in a dose-dependent manner. It further also inhibited growth of new and established A431 xenografts, a cell line expressing >10^6 EGFRs/cell (PMID: 11454674). The efficacy of this antibody, on the growth of intracranial xenografted gliomas in nude mice was also studied. It was reported that treatment of U87 MG.DEGFR tumors in mice with mAb 806 caused decreases in both tumor growth and angiogenesis, as well as increased apoptosis. In vivo mAb 806 treatment resulted in reduced phosphorylation of the constitutively active DEGFR and caused down-regulated expression of the apoptotic protector, Bcl-XL (PMID: 11454673).

Specifications

More Information
Brand	Vector Labs
UNSPSC	12161500

Reviews